JP2022542323A5 - - Google Patents
Info
- Publication number
- JP2022542323A5 JP2022542323A5 JP2022506188A JP2022506188A JP2022542323A5 JP 2022542323 A5 JP2022542323 A5 JP 2022542323A5 JP 2022506188 A JP2022506188 A JP 2022506188A JP 2022506188 A JP2022506188 A JP 2022506188A JP 2022542323 A5 JP2022542323 A5 JP 2022542323A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962880310P | 2019-07-30 | 2019-07-30 | |
| US62/880,310 | 2019-07-30 | ||
| PCT/US2020/043788 WO2021021761A1 (en) | 2019-07-30 | 2020-07-27 | Urea, amide, and substituted heteroaryl compounds for cbl-b inhibition |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022542323A JP2022542323A (ja) | 2022-09-30 |
| JP2022542323A5 true JP2022542323A5 (https=) | 2023-08-04 |
| JPWO2021021761A5 JPWO2021021761A5 (https=) | 2023-08-04 |
| JP7605824B2 JP7605824B2 (ja) | 2024-12-24 |
Family
ID=72087192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506188A Active JP7605824B2 (ja) | 2019-07-30 | 2020-07-27 | Ｃｂｌ－ｂの阻害のための尿素、アミド、および置換されたヘテロアリール化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220387395A1 (https=) |
| EP (1) | EP4003965A1 (https=) |
| JP (1) | JP7605824B2 (https=) |
| CN (1) | CN114450271B (https=) |
| AU (1) | AU2020320195A1 (https=) |
| CA (1) | CA3148769A1 (https=) |
| MX (1) | MX2022001199A (https=) |
| WO (1) | WO2021021761A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7600123B2 (ja) | 2018-10-15 | 2024-12-16 | ニューリックス セラピューティクス，インコーポレイテッド | ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物 |
| WO2020167518A1 (en) | 2019-02-13 | 2020-08-20 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| EP3953346A1 (en) | 2019-04-09 | 2022-02-16 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| EP3969447A1 (en) | 2019-05-17 | 2022-03-23 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof |
| MX2021015675A (es) | 2019-06-26 | 2022-02-03 | Nurix Therapeutics Inc | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos. |
| EP4034141A1 (en) | 2019-09-24 | 2022-08-03 | Nurix Therapeutics, Inc. | Cbl inhibitors and compositions for expansion of immune cells |
| US11820781B2 (en) | 2019-12-04 | 2023-11-21 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| CN115297861B (zh) * | 2020-01-29 | 2024-07-12 | 福宏治疗公司 | 化合物及其用途 |
| US12016860B2 (en) | 2021-04-08 | 2024-06-25 | Nurix Therapeutics, Inc. | Combination therapies with Cbl-b inhibitor compounds |
| WO2022272248A1 (en) * | 2021-06-21 | 2022-12-29 | Nimbus Clio, Inc. | Cbl-b modulators and uses thereof |
| CN113577265B (zh) * | 2021-08-04 | 2022-04-15 | 明济生物制药（北京）有限公司 | Til细胞及其制备方法以及在癌症治疗中的用途 |
| AU2022379494A1 (en) | 2021-10-26 | 2024-05-30 | Nurix Therapeutics, Inc. | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
| JP2024542117A (ja) | 2021-11-05 | 2024-11-13 | ジェネンテック， インコーポレイテッド | Ｃ－ｃｂｌに対して選択的なｃｂｌ－ｂ阻害剤としてのラクタム |
| TW202342013A (zh) * | 2022-02-10 | 2023-11-01 | 英屬開曼群島商百濟神州有限公司 | 雜環化合物、其組成物及用其進行治療之方法 |
| WO2023205180A1 (en) | 2022-04-19 | 2023-10-26 | Nurix Therapeutics, Inc. | Biomarkers for cbl, and compositions and methods for their use |
| WO2023250097A1 (en) | 2022-06-22 | 2023-12-28 | Nurix Therapeutics, Inc. | Combination therapies with cbl-b inhibitor compounds and antiemetic agents |
| CN119998282A (zh) * | 2022-07-12 | 2025-05-13 | 热点治疗公司 | 固体形式和使用方法 |
| JP2025523057A (ja) * | 2022-07-12 | 2025-07-17 | ホットスポット セラピューティクス インコーポレイテッド | がん処置における使用のためのｃｂｌ－ｂ阻害剤及び抗ｐｄ１／抗ｐｄ－ｌ１ |
| EP4554570A1 (en) * | 2022-07-12 | 2025-05-21 | Hotspot Therapeutics, Inc. | Treatment of cell proliferation-associated conditions using a combination of a clb-b inhibitor and an additional therapeutic agent |
| US20260028336A1 (en) * | 2022-07-20 | 2026-01-29 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| JP2025525947A (ja) | 2022-08-16 | 2025-08-07 | グレンマーク ファーマシューティカルズ エルティーディー | Ｃｂｌ－ｂ阻害剤としての置換ピリジノン化合物 |
| WO2024062363A1 (en) * | 2022-09-21 | 2024-03-28 | Glenmark Pharmaceuticals Ltd | Bicyclic heterocyclic compounds as cbl-b inhibitors |
| WO2024074977A1 (en) * | 2022-10-04 | 2024-04-11 | Pfizer Inc. | Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds |
| WO2024131939A1 (en) * | 2022-12-23 | 2024-06-27 | Insilico Medicine Ip Limited | Cbl-b inhibitors and methods of uses thereof |
| CN120584113A (zh) | 2023-01-19 | 2025-09-02 | 广州宇繁南图生物科技有限公司 | 一种杂环化合物及其制备方法和应用 |
| WO2024231852A1 (en) * | 2023-05-08 | 2024-11-14 | Glenmark Pharmaceuticals Ltd | Substituted biphenyl compounds as cbl-b inhibitors |
| AU2024353668A1 (en) * | 2023-09-28 | 2026-04-16 | Insilico Medicine Ip Limited | Cbl-b inhibitors and methods of uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5192553A (en) | 1987-11-12 | 1993-03-09 | Biocyte Corporation | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| HN2001000008A (es) * | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
| EP1227321A1 (en) | 2000-12-28 | 2002-07-31 | Institut für Bioanalytik GmbH | Reversible MHC multimer staining for functional purification of antigen-specific T cells |
| WO2004099388A2 (en) * | 2003-03-05 | 2004-11-18 | Proteologics, Inc. | Cbl-b polypeptides, complexes and related methods |
| WO2004085382A1 (ja) * | 2003-03-27 | 2004-10-07 | Kirin Beer Kabushiki Kaisha | 生体内リン輸送を阻害する化合物およびそれを含んでなる医薬 |
| ES2566502T3 (es) * | 2006-09-13 | 2016-04-13 | The Trustees Of Columbia University In The City Of New York | Agentes y métodos para provocar una respuesta inmune antitumoral |
| AT506041A1 (de) * | 2007-12-10 | 2009-05-15 | Univ Innsbruck | Verfahren zur erhöhung der immunreaktivität |
| MX342995B (es) | 2010-07-13 | 2016-10-21 | Anthrogenesis Corp | Métodos de generar células asesinas naturales. |
| EP2471548A1 (de) * | 2010-12-28 | 2012-07-04 | Apeiron Biologics AG | siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs |
| RU2763795C2 (ru) | 2014-04-23 | 2022-01-11 | Джуно Терапьютикс, Инк. | Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии |
| AU2015289644A1 (en) | 2014-07-15 | 2017-02-02 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| EP3325475B1 (en) * | 2015-07-17 | 2020-03-18 | Takeda Pharmaceutical Company Limited | Oxadiazole derivatives useful as hdac inhibitors |
| EP3138905A1 (en) | 2015-09-04 | 2017-03-08 | Miltenyi Biotec GmbH | Method for natural killer cell expansion |
| CN108884140B (zh) | 2015-12-03 | 2022-10-25 | 朱诺治疗学股份有限公司 | 修饰的嵌合受体及相关组合物和方法 |
| WO2017107907A1 (zh) | 2015-12-25 | 2017-06-29 | 四川海思科制药有限公司 | 稠合环γ-氨基酸衍生物及其制备方法和在医药上的应用 |
| WO2019148005A1 (en) * | 2018-01-26 | 2019-08-01 | Nurix Therapeutics, Inc. | Inhibitors of cbl-b and methods of use thereof |
-
2020
- 2020-07-27 WO PCT/US2020/043788 patent/WO2021021761A1/en not_active Ceased
- 2020-07-27 CN CN202080068222.0A patent/CN114450271B/zh active Active
- 2020-07-27 MX MX2022001199A patent/MX2022001199A/es unknown
- 2020-07-27 JP JP2022506188A patent/JP7605824B2/ja active Active
- 2020-07-27 US US17/631,886 patent/US20220387395A1/en active Pending
- 2020-07-27 CA CA3148769A patent/CA3148769A1/en active Pending
- 2020-07-27 EP EP20757062.3A patent/EP4003965A1/en active Pending
- 2020-07-27 AU AU2020320195A patent/AU2020320195A1/en not_active Abandoned